BOT+BAL

Lexington, Mass. – August 28, 2026 Agenus Inc. announced the publication of mature Phase 1b results evaluating botensilimab (BOT)...

LEXINGTON, Mass., August 6, 2026 Agenus Inc. reported its second-quarter 2026 financial results while outlining significant progress in advancing...

LEXINGTON, Mass., July 6, 2026 Agenus announced new three-year follow-up results from the fully enrolled Phase 1b C-800-01 study...